Picard Medical / SynCardia Highlights Total Artificial Heart Bridge to Transplant Case at Texas Children's Hospital
Rhea-AI Summary
Picard Medical (NYSE American: PMI) highlighted use of the SynCardia Total Artificial Heart (STAH) as a bridge to transplant at Texas Children’s Hospital for a 21-year-old re-transplant patient.
The patient was supported on the STAH for approximately two and a half months before receiving a donor heart and subsequent successful transplant and discharge. The STAH replaces both ventricles for end-stage biventricular failure; Picard is also developing the fully implantable Emperor Total Artificial Heart.
AI-generated analysis. Not financial advice.
Positive
- STAH support duration of approximately 2.5 months enabled bridge-to-transplant
- FDA and Health Canada approvals for the SynCardia Total Artificial Heart noted
Negative
- None.
News Market Reaction – PMI
On the day this news was published, PMI declined 1.81%, reflecting a mild negative market reaction. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $67.91M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PMI was up 1.53% while key peers were mixed: KIDS gained 5.18%, CTKB 0.87%, LAB 0.28%, and AVMR/ZIMV were flat. Momentum scanner names (BVS up 5.65%, TMCI down 2.82%) also showed no unified sector direction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Tech week keynote | Positive | -9.4% | Announcement of SynCardia COO keynote on next-gen artificial heart technology. |
| Apr 01 | Patient event | Neutral | +1.0% | Participation in Voice of the Patient event focused on heart failure care. |
| Mar 25 | Full-year earnings | Neutral | +3.0% | 2025 results with revenue growth, higher cash, but wider net loss. |
| Mar 20 | ACC data preview | Positive | +2.7% | Plan to present early preclinical data on Emperor Total Artificial Heart. |
| Mar 19 | Bridge-to-transplant case | Positive | -3.5% | Highlight of second successful SynCardia bridge-to-transplant case at UCSF. |
Clinical and event-driven news often see modestly aligned moves, but there are instances where positive case highlights were followed by short-term pullbacks.
Over recent months, Picard Medical has balanced financial updates with growing clinical and visibility milestones. The Mar 25 earnings detailed 2025 revenue growth and higher cash, while multiple Mar 19 and prior 8-Ks highlighted successful SynCardia Total Artificial Heart bridge-to-transplant cases and upcoming Emperor platform presentations. The current Texas Children’s Hospital case continues this pattern of showcasing complex real-world use, reinforcing prior narratives around clinical adoption and next-generation development.
Market Pulse Summary
This announcement highlights a complex re-transplant case in which a 21-year-old patient, first transplanted in 2017 at age 13, was supported on the SynCardia Total Artificial Heart for roughly two and a half months before successful re-transplant. It reinforces the device’s role in advanced biventricular failure and underscores plans for the fully implantable Emperor system. Investors may track additional case reports, regulatory milestones, and Emperor development updates as indicators of future adoption.
Key Terms
total artificial heart medical
bridge to heart transplantation medical
biventricular failure medical
mechanical circulatory support medical
congenital heart disease medical
AI-generated analysis. Not financial advice.
SynCardia Total Artificial Heart supports patient through complex re-transplant journey
TUCSON, Ariz., April 15, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted the successful use of the SynCardia Total Artificial Heart (“STAH”) as a bridge to heart transplantation at Texas Children’s Hospital (“Texas Children’s”), supporting a 21-year-old patient through a complex re-transplant journey.
Texas Children’s recently featured the case of Gregory, a now 21-year-old patient who had received his first heart transplant at Texas Children’s in 2017 at the age of 13 following multiple congenital heart defects. In early 2025, Gregory was admitted to Texas Children’s after presenting with chest pain and was diagnosed with rejection of his first transplanted heart. With his original transplant no longer viable and a donor heart unavailable, surgeons implanted the STAH to provide full circulatory support. Gregory was supported on the STAH for approximately two and a half months before a suitable donor heart became available. He subsequently underwent successful heart transplantation and, following an extended recovery, was discharged from the hospital.
The STAH is designed to replace the function of both ventricles in patients with end-stage biventricular failure, enabling stabilization, organ recovery, and improved candidacy for transplantation. Its use in complex clinical scenarios, including re-transplantation in young adults with congenital heart disease, demonstrates the flexibility and durability of the therapy in supporting some of the most critically ill patients.
Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, commented, “Performing a successful re-transplantation in a young adult with congenital heart disease is among the most complex scenarios in cardiac surgery. In this instance at Texas Children’s, the STAH allowed the clinical team to stabilize the patient and effectively buy time following the diagnosis of rejection until a suitable donor organ became available. Although the support period in this case was relatively short compared with many other cases, the immediate availability of the STAH was essential in enabling a successful outcome. Experiences like this also reinforce why we are developing the Emperor Total Artificial Heart, our next generation fully implantable total artificial heart, designed to remove the external driver and ultimately serve as a potential alternative to heart transplantation for certain patients.”
Picard Medical continues to support leading transplant centers across the United States and globally, advancing the use of the STAH to improve outcomes for patients with advanced heart failure. Picard is also advancing development of the Emperor Total Artificial Heart, a fully implantable next-generation device designed to expand access to long-term mechanical circulatory support without the need for external pneumatic drivers.
About Texas Children’s Hospital
Texas Children's, a nonprofit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children's hospital in Texas and among the top in the nation, Texas Children's has garnered widespread recognition for its expertise and breakthroughs in pediatric and women's health. The system includes the Texas Children's Duncan NRI; the Feigin Tower for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; Texas Children's Hospital The Woodlands, the first hospital devoted to children's care for communities north of Houston; and Texas Children's Hospital North Austin, the new state-of-the-art facility providing world-class pediatric and maternal care to Austin families. The organization also created Texas Children's Health Plan, the nation's first HMO focused on children; Texas Children's Pediatrics, the largest pediatric primary care network in the country; Texas Children's Urgent Care clinics that specialize in after-hours care tailored specifically for children; and a global health program that is channeling care to children and women all over the world. Texas Children's Hospital is affiliated with Baylor College of Medicine. For more information, visit www.texaschildrens.org.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company's filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC’s website at http://www.sec.gov and on the Company's investor relations website at https://picardmedical.com/.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
Picard Medical, Inc./SynCardia Systems, LLC
General/Media
Brittany Lanza
